Clinical Trials Directory

Trials / Completed

CompletedNCT00984256

Weekly Dosing of Malarone ® for Prevention of Malaria

Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
35 (actual)
Sponsor
U.S. Army Medical Research and Development Command · Federal
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.

Detailed description

In this study, two groups of volunteers will be exposed to malaria through the bites of infected mosquitoes. In one group, volunteers will be randomly assigned to one of 5 arms. Each of these arms will receive a different dose of Malarone®, a drug known to prevent malaria when taken daily. Each of these doses will be lower than the maximum approved dose of this medicine. The other group will not be treated with any drug that could prevent symptoms or infection. After exposure, both groups will be monitored for a period of approximately 3 months to see if they develop symptoms of malaria. Any subjects who do so will be treated with appropriate medications. Subjects in both groups will have their blood checked regularly during this period for the presence of malaria parasites. At the completion of the study, results will be analyzed to determine whether any of the doses of Malarone might effectively prevent malaria if taken weekly rather than daily.

Conditions

Interventions

TypeNameDescription
DRUGAtovaquone ProguanilVolunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
OTHERProcedure - malaria challenge2\) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.

Timeline

Start date
2009-09-01
Primary completion
2010-04-01
Completion
2010-04-01
First posted
2009-09-25
Last updated
2013-11-25
Results posted
2013-11-25

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00984256. Inclusion in this directory is not an endorsement.